137 related articles for article (PubMed ID: 16258942)
21. Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases.
Bousquet M; Gibrat C; Ouellet M; Rouillard C; Calon F; Cicchetti F
J Neurochem; 2010 Sep; 114(6):1651-8. PubMed ID: 20569301
[TBL] [Abstract][Full Text] [Related]
22. Drug-induced hyperthermia in Huntington's disease.
Gaasbeek D; Naarding P; Stor T; Kremer HP
J Neurol; 2004 Apr; 251(4):454-7. PubMed ID: 15083292
[TBL] [Abstract][Full Text] [Related]
23. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
25. Drug discovery and development for Huntington's disease - an orphan indication with high medical need.
Heitz F; La Rosa S; Gonzalez-Couto E; Gaviraghi G; Terstappen GC
IDrugs; 2008 Sep; 11(9):653-60. PubMed ID: 18763216
[TBL] [Abstract][Full Text] [Related]
26. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease.
Ondo WG; Mejia NI; Hunter CB
Parkinsonism Relat Disord; 2007 Oct; 13(7):453-4. PubMed ID: 17046312
[No Abstract] [Full Text] [Related]
27. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.
Pinto JT; Van Raamsdonk JM; Leavitt BR; Hayden MR; Jeitner TM; Thaler HT; Krasnikov BF; Cooper AJ
J Neurochem; 2005 Aug; 94(4):1087-101. PubMed ID: 15992377
[TBL] [Abstract][Full Text] [Related]
28. Normal and pathological aging of attention in presymptomatic Huntington's, Huntington's and Alzheimer's Disease, and nondemented elderly subjects.
Peretti CS; Ferreri F; Blanchard F; Bakchine S; Peretti CR; Dobrescu A; Chouinard VA; Chouinard G
Psychother Psychosom; 2008; 77(3):139-46. PubMed ID: 18277060
[TBL] [Abstract][Full Text] [Related]
29. Drug shows potential for treatment of Huntington's disease.
Frankish H
Lancet Neurol; 2006 Jun; 5(6):476-7. PubMed ID: 16739299
[No Abstract] [Full Text] [Related]
30. Efficacy of levetiracetam in Huntington disease.
de Tommaso M; Di Fruscolo O; Sciruicchio V; Specchio N; Cormio C; De Caro MF; Livrea P
Clin Neuropharmacol; 2005; 28(6):280-4. PubMed ID: 16340384
[TBL] [Abstract][Full Text] [Related]
31. Metformin therapy in a transgenic mouse model of Huntington's disease.
Ma TC; Buescher JL; Oatis B; Funk JA; Nash AJ; Carrier RL; Hoyt KR
Neurosci Lett; 2007 Jan; 411(2):98-103. PubMed ID: 17110029
[TBL] [Abstract][Full Text] [Related]
32. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent.
Shults C; Steardo L; Barone P; Mohr E; Juncos J; Serrati C; Fedio P; Tamminga CA; Chase TN
Neurology; 1986 Aug; 36(8):1099-102. PubMed ID: 2874527
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of rapid dose administration of quetiapine in bipolar mania.
Hatim A; Habil H; Jesjeet SG; Low CC; Joseph J; Jambunathan ST; Zuraida NZ
Hum Psychopharmacol; 2006 Jul; 21(5):313-8. PubMed ID: 16856220
[TBL] [Abstract][Full Text] [Related]
34. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease.
Constantinescu R; Romer M; Oakes D; Rosengren L; Kieburtz K
Parkinsonism Relat Disord; 2009 Mar; 15(3):245-8. PubMed ID: 19056308
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease.
Verny C; Bachoud-Lévi AC; Durr A; Goizet C; Azulay JP; Simonin C; Tranchant C; Calvas F; Krystkowiak P; Charles P; Youssov K; Scherer C; Prundean A; Olivier A; Reynier P; Saudou F; Maison P; Allain P; von Studnitz E; Bonneau D;
Mov Disord; 2017 Jun; 32(6):932-936. PubMed ID: 28436572
[TBL] [Abstract][Full Text] [Related]
36. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
37. Cysteamine: an old drug with new potential.
Besouw M; Masereeuw R; van den Heuvel L; Levtchenko E
Drug Discov Today; 2013 Aug; 18(15-16):785-92. PubMed ID: 23416144
[TBL] [Abstract][Full Text] [Related]
38. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
[TBL] [Abstract][Full Text] [Related]
39. Nephropathic cystinosis in children: An overlooked disease.
Soliman NA; El-Baroudy R; Rizk A; Bazaraa H; Younan A
Saudi J Kidney Dis Transpl; 2009 May; 20(3):436-42. PubMed ID: 19414947
[TBL] [Abstract][Full Text] [Related]
40. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
